Experimental induction of reparative morphogenesis and adaptive reserves in the ischemic myocardium using multipotent mesenchymal bone marrow-derived stem cells

Pathophysiology

Volumn 23, Issue 2, 2016, Pages 95-104

  Mykhaylichenko, V Yu ^a   Kubyshkin, A V ^a   Samarin, S A ^a   Fomochkina, I I ^a   Anisimova, L V ^a  

^a V I VERNADSKY CRIMEAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

Mesenchymal stem cells; Myocardial infarction; Myocardial regeneration

Indexed keywords

ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR 2; NITRIC OXIDE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CARDIOMYOPLASTY; CELL DIFFERENTIATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE ISCHEMIA; HEART STROKE VOLUME; LYMPHOCYTIC INFILTRATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

EID: 84968754745     PISSN: 09284680     EISSN: 1873149X     Source Type: Journal    
DOI: 10.1016/j.pathophys.2016.04.002     Document Type: Article

References (49)

1. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur. Heart J. 2014, 42:2950-2959.
2. Makino S., Fukuda K., Miyoshi S., Konishi F., Kodama H., Pan J., Sano M., Takahashi T., Hori S., Abe H., Hata J.I., Umezawa A., Ogawa S. Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest. 1999, 103:697-705.
3. Waheed I.N., Mnati I.M., Kadhim A.H.H. In vitro study of adult bone marrow mesenchymal stem cells derived from albino rats and their cardiomyogenic differentiation. Jordan J. Biol. Sci. 2010, 3:185-192.
4. Williams R., Hare J.M. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ. Res. 2011, 109:923-940.
5. Yu Plotnikov E., Zdorov D.B., Suhikh G.T. Stem cells in regenerative therapy of cardiac pathology. The role of intercellular interactions: scholarly. J. Cell. Transplant. Tissue Eng. 2009, 4:43-49.
6. Kruglyakov P.V., Lochmatov E.A., Klimovich V.B., Yu Zaritsky A. Mesenchymal stem cells and immunopathological condition of the body: scholarly. J. Cell. Transplant. Tissue Eng. 2006, 3:36-41.
7. Brune J.C., Tormin A., Johansson M.C., Rissler P., Brosjo O., Lofvenberg R., von Steyern F.V., Mertens F., Rydholm A., Scheding S. Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly similar to their bone marrow counterparts. Int. J. Cancer. 2011, 129:319-330.
8. Smolyaninov A.B., Ivolgin D.A., Aizenshtadt A.A. Mesenchymal stem cells: perspectives of cardiologic application. Cardiol. Vestnik. 2013, 8:5-11.
9. Gu E., Chen W.Y., Gu J., Burridge P., Wu J.C. Molecular imaging of stem cells: tracking survival, biodistribution, tumorigenicity, and immunogenicity. Theranostics 2012, 2:335-345.
10. Doppler S.A., Deutsch M., Lange R., Krane M. Cardiac regeneration: current therapies-future concepts. J. Thorac. Dis. 2013, 5:683-697.
11. Robey T.E., Saiget M.K., Reinecke H., Murry C.E. Systems approaches to preventing transplanted cell death in cardiac repair. J. Mol. Cell. Cardiol. 2008, 45:567-581.
12. Baglio S.R., Pegtel D.M., Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front. Physiol. 2012, 3:359-370.
13. Zhang Y., Wang Y., Wang L., Wang Y., Cai X., Zhang C., Wang L.V., Xia Y. Labeling human mesenchymal stem cells with Au nanocages for in vitro and in vivo tracking by two-Photon microscopy and photoacoustic microscopy. Theranostics 2013, 3:532-543.
14. Vladimirskaya Ye.B. Mesenchymal stem cells (MSCs) in cell therapy. Oncohematology 2007, 1:4-14.
15. Soleymaninejadian E., Pramanik K., Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am. J. Reprod. Immunol. 2012, 67:1-8.
16. Sackstein R. Glycoengineering of HCELL, the human bone marrow homing receptor: sweetly programming cell migration. Ann. Biomed. Eng. 2012, 40:766-776.
17. Hsiao S.T., Asgari A., Lokmic Z., Sinclair R., Dusting G.J., Lim S.Y., Dilley R.J. Paracrine Factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev. 2012, 21:2189-2203.
18. Lin T.M., Chang H.M., Wang K.H., Kao A.P., Chang C.C., Wen C.Y., Lai C.S., Lin S.D. Isolation and identification of mesenchymal stem cells from human lipoma tissue. Biochem. Biophys. Res. Commun. 2007, 361:883-889.
19. Yang J., Zhang H., Zhao L., Chen Y., Liu H., Zhang T. Human adipose tissue-derived stem cells protect impaired cardiomyocytes from hypoxia/reoxygenation injury through hypoxia-induced paracrine mechanism. Cell Biochem. Funct. 2012, 30:505-514.
20. Xu X., Zhang X., Wang S., Qian H., Zhu W., Cao H., Wang M., Chen Y., Xu W. Isolation and comparison of mesenchymal stem-like cells from human gastric cancer and adjacent non-cancerous tissues. J. Cancer Res. Clin. Oncol. 2011, 137:495-504.
21. Kern S., Eichler H., Stoeve J., Klüter H., Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow umbilical cord blood, or adipose tissue. Stem Cells 2006, 24:1294-1301.
22. Ilic D., Polak J. Stem cell based therapy-where are we going?. Lancet 2012, 379:877-878.
23. Carvalho J.L., Braga V.B.A., Melo M.B., Campos A.C., Oliveira M.S., Gomes D.A., Ferreira A.J., Santos R.A., Goes A.M. Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction. J. Cell. Mol. Med. 2013, 17:617-625.
24. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005, 18:1440-1463.
25. Chamberlain M.D., Gupta R., Sefton M.V. Bone marrow-Derived mesenchymal stromal cells enhance chimeric vessel development driven by endothelial cell-Coated microtissues. Tissue Eng. Part. A. 2012, 18:285-294.
26. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop Dj., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
27. Yoon J., Min B.G., Kim Y.H., Shim W.J., Ro Y.M., Lim D.S. Differentiation, engraftment and functional effects of pre-treated mesenchymal stem cells in a rat myocardial infarct model. Acta Cardiol. 2005, 60:277-284.
28. Barbash I.M., Chouraqui P., Baron J., Feinberg M.S., Etzion S., Tessone A., Miller L., Guetta E., Zipori D., Kedes L.H., Kloner R.A., Leor J. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003, 108:863-868.
29. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., Shpall E.J., McCarthy P., Atkinson K., Cooper B.W., Gerson S.L., Laughlin M.J., Loberiza F.R., Moseley A.B., Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 2005, 11:389-398.
30. Moradi K., Abbasi M., Aboulhasani F., Abbasi N., Babatunde K.A., Sargolzaeiaval F., Dehpour A.R. Therapeutic angiogenesis promotes efficacy of human umbilical cord matrix stem cell transplantation in cardiac repair. Iran J. Basic Med. Sci. 2015, 18:563-570.
31. Zhang L., Li Y., Zhang C., Chopp M., Gosiewska A., Hong K. Delayed administration of human umbilical tissue-derived cells improved neurological functional recovery in a rodent model of focal ischemia. Stroke 2011, 1437-1444.
32. Emmert M.Y., Weber B., Wolint P., Frauenfelder T., Zeisberger S.M., Behr L. Intramyocardial transplantation and tracking of human mesenchymal stem cells in a novel intra-uterine pre-immune fetal sheep myocardial infarction model: a proof of concept study. PLoS One 2013, 8:e57759.
33. Hou J., Yan P., Guo T., Xing Y., Zheng S., Zhou C., Huang H., Long H., Zhong T., Wu Q., Wang J., Wang T. Cardiac stem cell transplantation enhances the expression of connexin-43 via the ANG II/AT1R/TGF-beta1 signaling pathway in a rat model of myocardial infarction. Exp. Mol. Pathol. 2015, 3:693-701.
34. Singelyn J.M., Sundaramurthy P., Johnson T.D., Schup-Magoffin P.J., Hu D.P., Faulk D.M., Wang J., Mayle K.M., Bartels K., Salvatore M., Kinsey A.M., DeMaria A.N., Dib N., Christman K.L. Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J. Am. Coll. Cardiol. 2012, 59:751-763.
35. Roe M.T., Messenger J.C., Weintraub W.S., Cannon C.P., Fonarow G.C., Dai D., Chen A.Y., Klein L.W., Masoudi F.A., McKay C., Hewitt K., Brindis R.G., Peterson E.D., Rumsfeld J.S. Treatments trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J. Am. Coll. Cardiol. 2010, 4:254-263.
36. Segers V.F., Lee R.T. Stem-cell therapy for cardiac disease. Nature 2008, 7181:937-942.
37. Christ G.J., Saul J.M., Furth M.E., Andersson K.E. The pharmacology of regenerative medicine. Pharmacol. Rev. 2013, 65:1091-1133.
38. Wei X., Yang X., Han Z., Qu F., Shao L., Shi Y. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol. Sin. 2013, 34:747-754.
39. Schepotin I.B. Stem cells: progress, problems and prospects. J. Ukr. Natl. Acad. Med. Sci. 2011, 17:54-61.
40. Nagaya N., Kangawa K., Itoh T., Iwase T., Murakami S., Miyahara Y., Fujii T., Uematsu M., Ohgushi H., Yamagishi M., Tokudome T., Mori H., Miyatake K., Kitamura S. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005, 8:1128-1135.
41. Savoye C., Equine O., Tricot O., Nugue O., Segrestin B., Sautiere K., Elkohen M., Pretorian E.M., Taghipour K., Philias A., Aumegeat V., Decoulx E., Ennezat P.V., Bauters C. Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice. Am. J. Cardiol. 2006, 9:1144-1149.
42. Jiang Q., Song P., Wang E., Li J., Hu S., Zhang H. Remote ischemic postconditioning enhances cell retention in the myocardium after intravenous administration of bone marrow mesenchymal stromal cells. J. Mol. Cell Cardiol. 2013, 56:1-7.
43. Timmers L., Lim S.K., Hoefer I.E., Arslan F., Lai R.C., van Oorschot A.A., Goumans M.J., Strijder C., Sze S.K., Choo A., Piek J.J., Doevendans P.A., Pasterkamp G., de Kleijn D.P. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res. 2011, 3:206-214.
44. Vassalli G., Moccetti T. Cardiac repair with allogeneic mesenchymal stem cells after myocardial infarction. Swiss. Med. Wkly. 2011, 141:w13209.
45. Cochain C., Channon K.M., Silvestre J.S. Angiogenesis in the infarcted myocardium. Antioxid. Redox. Signal. 2013, 9:1100-1113.
46. Zhao T., Zhao W., Chen Y., Ahokas R.A., Sun Y. Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction. Microvasc. Res. 2010, 2:188-194.
47. Grin V.K., Shtutin A.A., Yu Mykhaylichenko V. The use of autologous mesenchymal stem cells in cardiology and traumatology. J. Ukr. Natl. Acad. Med. Sci. 2011, 17:67-75.
48. Mathieu E., Lamirault G., Toquet C., Lhommet P., Rederstorff E., Sourice S., Biteau K., Hulin P., Forest V., Weiss P., Guicheux J., Lemarchand P. Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction. PLoS One 2012, 12:e51991.
49. Imanishi Y., Saito A., Komoda H., Kitagawa-Sakakida S., Miyagawa S., Kondoh H., Ichikawa H., Sawa Y. Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats. J. Mol. Cell Cardiol. 2008, 4:662-671.